Aleafia Health Inc

Aleafia Health — Q3 2023 Earnings Presentation

26 slides from Aleafia Health's earnings presentation, Feb 13, 2023

  1. Slide 1: Q3 Fiscal Year 2023 Earnings Presentation

    February 13, 2023 Q3 Fiscal Year 2023 Earnings Presentation AleafiaHealth.com

  2. Slide 2: Disclaimer

    Disclaimer FORWARD LOOKING INFORMATION Certain statements herein relating to the Company constitute “forward looking information”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs,

  3. Slide 3: Presenters

    Presenters Executive Leadership Tricia Symmes Matt Sale Chief Executive Officer Chief Financial Officer 20+ years as a senior executive in the pharmaceutical, biotech, consumer packaged goods, 17+ years of increasingly more senior finance executive experience. Deep capital markets, and cannabis indu

  4. Slide 4: New Milestone Achievements

    New Milestone Achievements Q3 FY2023 Financial Outperformance with Aleafia Delivering Profitability for the Second Consecutive Quarter Adjusted EBITDA Profitability Cost Rationalizations International Growth • 2nd consecutive quarter • Historical low in Adjusted SG&A (51% • $1.0 million internationa

  5. Slide 5: 4 Core Strategic Objectives

    4 Core Strategic Objectives Continues to Demonstrate Growth and Leadership Across all Four Strategic Pillars on our Path to Profitability Top 10 Adult-Use Adjusted EBITDA Leadership in Medical Growing International Market Position (1) Profitability • Divvy leadership in Ontario value • Record month

  6. Slide 6: Transformation to Branded Producer with Positive Adjusted EBITDA Profile

    Transformation to Branded Producer with Positive Adjusted EBITDA Profile Monumental Net Revenue Growth in Branded Portfolio vs. Wholesale Decline Intentional strategic shift to a branded product portfolio strategy has driven consistent growth in net revenue and improvements in Adjusted EBITDA profit

  7. Slide 7: Business Overview & Performance

    Business Overview & Performance Q3 | FY2023 Earnings Presentation

  8. Slide 8: Q3 FY2023 Highlights: Adult-Use Sales Channel

    Q3 FY2023 Highlights: Adult-Use Sales Channel Robust Growth in Adult-Use Net Revenue Year over Year Driven by Flagship Divvy Brand Adult-Use Revenue Divvy Entrenchment in Adult-Use Market 11% growth in total revenue over prior year 4% growth in net revenue over prior year #4 ranked Divvy pre-roll br

  9. Slide 9: Divvy: A Brand with Impact, Featuring Aleafia-Grown Flower and More

    Divvy: A Brand with Impact, Featuring Aleafia-Grown Flower and More Divvy’s high-volume brand capitalizes on Port Perry outdoor flower, and a fun, curated portfolio with high margin product formats pre-rolls, milled flower, vapes & more to come. 9

  10. Slide 10: Brand Highlights: Flagship Holiday Window in High Traffic Shopping District

    Brand Highlights: Flagship Holiday Window in High Traffic Shopping District First consumer-facing window display at high-traffic Yonge Dundas Square in Toronto over Holiday season Holiday Marketing Activation & PR Event Divvy & Bogart’s Kitchen featured at flagship retail store in Toronto’s Yonge Du

  11. Slide 11: Port Perry Sun Grown Flower Dominates Divvy Portfolio

    Port Perry Sun Grown Flower Dominates Divvy Portfolio Changes in Growing Practices Increase Usable Flower Supply for Best-Selling Branded Products Progress Towards Top 10 Market Share Targets In Ontario (1) Category Market Share Market Share Rank Progress Pre-Rolls 4.4% #4 ✓ Milled Flower 6.1% #4 ✓

  12. Slide 12: Q3 FY2023 Highlights: Medical Sales Channel

    Q3 FY2023 Highlights: Medical Sales Channel Growth in Product Portfolio and Outreach For Patient Groups Offset Industry Trends and Increase Year-Over-Year Growth in New Markets Medical Net Revenue (excl. Clinic Revenue) ● 26% growth over the prior year in medical net revenue (excluding clinic revenu

  13. Slide 13: Q3 FY2023 Highlights: International Sales Channel

    Q3 FY2023 Highlights: International Sales Channel ● Revenue +155% year over year growth ● New est. $1.0 million(1) European partnership ○ Improved access into Europe ○ Customer diversification ● Executed shipment under previously announced est. $4.6 million(1), 2-year sales commitment ○ Product is n

  14. Slide 14: Financial Overview

    Financial Overview Q3 | FY2023 Earnings Presentation

  15. Slide 15: Key Financial Highlights of Q3 FY2023

    Key Financial Highlights of Q3 FY2023 Strong results on all key performance indicators leading to profitable growth Total revenue and net revenue increased by +23% Adult-Use • Net revenue increased by $0.2 million, or +4%, over the prior year • Strong pre-roll and milled flower performance • Flower

  16. Slide 16: Significant Cost Rationalizations in Adjusted SG&A to Dramatically Reduce Cash Burn

    Significant Cost Rationalizations in Adjusted SG&A to Dramatically Reduce Cash Burn Current Adjusted SG&A Profile Flexible and Scalable to Facilitate Continued Net Revenue Growth 51% Reduction in Adjusted SG&A Over the Last 4 Quarters ● Enhanced procurement process ● Ongoing vendor consolidation ● N

  17. Slide 17: Focused on Expanding Adjusted EBITDA Profitability

    Focused on Expanding Adjusted EBITDA Profitability Branded Cannabis Product Portfolio is Driving Revenue Growth at Attractive Margins Leading to Enhanced Profitability Adjusted EBITDA Profitability Trend (Last 6 Quarters) Net Revenue Growth ● Further brand rationalizations to focus on Divvy ● SKU ra

  18. Slide 18: Benchmarking Adjusted EBITDA Profitability Against Peers

    Benchmarking Adjusted EBITDA Profitability Against Peers Driving Improved Adjusted EBITDA Margin Profitability, a Key Lever on the Pathway to Operating Cash Flow Profitability Latest Quarter Adjusted EBITDA Margin vs Industry Peers(1) 2nd 2nd Top quartile Adjusted EBITDA margin profitability driven

  19. Slide 19: Strong Growth and Adjusted EBITDA Profitability a Catalyst for Potential Valuation Re-Rate

    Strong Growth and Adjusted EBITDA Profitability a Catalyst for Potential Valuation Re-Rate Top Quartile Retail Sales Pull through Growth Rates Combined Profitability Provides Opportunity for Robust Shareholder Returns Retail Sell Through CQGR Since Q1 2021 (1)(2) EV / 2023E Net Revenue (3) (4) Aleaf

  20. Slide 20: Outperforming Profitability Targets

    Outperforming Profitability Targets Well-Ahead of Plan on Adjusted EBITDA Profitability (1) Branded cannabis portfolio growth strategy working Progress Toward Targets (1) • Top 5 player in Ontario pre-roll • Top 5 player in Ontario milled • Medical business continues to capture market share • Intern

  21. Slide 21: Multi-Pronged Growth Strategy Across Three High Value Pillars

    Multi-Pronged Growth Strategy Across Three High Value Pillars Initiatives Underway to Drive Net Revenue Growth Across All Sales Channels for Branded Cannabis Product Portfolio Net Revenue Composition and Adjusted EBITDA Adult-Use ● Own pre-roll with multiple pack sizes, larger “refill” offerings ● N

  22. Slide 22: End Remarks

    End Remarks Executive Leadership Q3 | FY2023 Earnings Presentation

  23. Slide 23: Q&A

    Q&A Q3 | FY2023 Earnings Presentation

  24. Slide 24: Current Capitalization

    Current Capitalization Balance Sheet Transformation in Progress; Near-term Liquidity from Receivables Facility and No Near-term Refinancings Required Liquidity to Drive Growth • Up to $7 Million Receivables Facility ($6.6 million undrawn at Dec 31, 2022) Credit Facilities • $19 Million Credit Facili

  25. Slide 25: Non-IFRS Measures - Adjusted EBITDA

    Non-IFRS Measures - Adjusted EBITDA ($,M's) Q3 FY2022 Q4 FY2022 Q5 FY2022 Q1 FY2023 Q2 FY2023 Q3 FY2023 Net loss -80.4 -71.5 -4.2 -4.5 7.0 -25.1 Add back: Depreciation and amortization 1.9 3.7 2.1 2.0 2.0 1.3 Interest expense, net 2.0 2.2 2.6 2.8 2.1 2.2 Income tax expense (recovery) -2.9 0.0 0.0 0.

  26. Slide 26: Non-IFRS Measures - Adjusted SG&A

    Non-IFRS Measures - Adjusted SG&A Note: See Cautionary Statement Regarding Non-IFRS Measures Q3 | FY2023 Earnings Presentation 26

Aleafia Health — Q3 2023 Earnings Presentation on 6ix